Horizon Pharma PLC (HZNP)

NASDAQ
93.88
-0.73(-0.77%)
After Hours
94.00
+0.12(+0.13%)
- Real-time Data
  • Volume:
    2,132,140
  • Bid/Ask:
    94.00/97.00
  • Day's Range:
    93.52 - 96.40

HZNP Overview

Prev. Close
94.61
Day's Range
93.52-96.4
Revenue
2.19B
Open
94.92
52 wk Range
52.73-97.36
EPS
1.15
Volume
2,132,140
Market Cap
21.1B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,624,457
P/E Ratio
82.06
Beta
1.09
1-Year Change
87.87%
Shares Outstanding
224,768,551
Next Earnings Date
10 Aug 2021
What is your sentiment on Horizon Pharma PLC?
or
Market is currently closed. Voting is open during market hours.

Horizon Pharma PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong SellStrong BuyStrong BuyStrong Buy
SummaryBuyNeutralStrong BuyStrong BuyStrong Buy

Horizon Pharma PLC Company Profile

Horizon Pharma PLC Company Profile

Employees
1640

Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.